---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-097921"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2021-07-30T23:59:59+00:00"
generated_at: "2026-06-30T00:17:37.813719+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iRadimed Q2 2021 revenue $9.8M, GAAP EPS $0.12; guides FY21 rev $40.0-40.4M

## Summary
- Q2 2021 revenue $9.8M, up 44% YoY from $6.8M; net income $1.5M vs net loss of $2.1M.
- GAAP diluted EPS $0.12; non-GAAP diluted EPS $0.14, up from $0.05 in Q2 2020.
- Q3 2021 guidance: rev $10.3-10.5M, GAAP EPS $0.14-0.15, non-GAAP EPS $0.16-0.17.
- Full-year 2021 guidance: rev $40.0-40.4M, GAAP EPS $0.53-0.55, non-GAAP EPS $0.60-0.62.
- Cash and investments $56.1M at quarter-end; operating cash flow $4.5M YTD.

## SEC filing metadata
- accession: 0001104659-21-097921
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2021-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000110465921097921/0001104659-21-097921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000110465921097921/tm2123649d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-097921
- JSON: https://secwatch.observer/filing/0001104659-21-097921.json
- Plain text: https://secwatch.observer/filing/0001104659-21-097921.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.